By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Vaccine combinations > Tetanus, diphtheria, acellular pertussis vaccine (tdap) > Diphtheria Toxoid / Pertussis, Acellular / Tetanus Toxoid Dosage
Vaccine combinations
https://themeditary.com/dosage-information/diphtheria-toxoid-pertussis-acellular-tetanus-toxoid-dosage-6951.html

Diphtheria Toxoid / Pertussis, Acellular / Tetanus Toxoid Dosage

Drug Detail:Tetanus, diphtheria, acellular pertussis vaccine (tdap) (Tetanus, diphtheria, acellular pertussis vaccine (tdap) [ tet-a-nus, dif-theer-ee-a, and-ay-sel-yoo-ler-per-tus-iss ])

Drug Class: Vaccine combinations

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Diphtheria Prophylaxis

ADACEL(R):
10 to 64 years old: 0.5 mL intramuscularly once

  • Routine booster vaccination should be 5 or more years after the last recommended dose of the diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) series.
  • May use as a booster dose 8 years after the first tetanus toxoid, reduced diphtheria and acellular pertussis vaccine, adsorbed (Tdap) dose.
  • May use for tetanus prophylaxis in wound management if at least 5 years have elapsed since a previous tetanus toxoid containing vaccine dose.

BOOSTRIX(R): 0.5 mL intramuscularly once
  • Administer 5 years after the last recommended dose of the DTaP series.
  • There are no data to support repeat administration of BOOSTRIX(R), or for its use for primary immunization.
  • May use for tetanus prophylaxis in wound management if no previous dose of any Tdap has been given.


Uses:
  • Booster immunization after completion of primary diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) vaccine series.
  • Tetanus prophylaxis in wound management.

Usual Adult Dose for Pertussis Prophylaxis

ADACEL(R):
10 to 64 years old: 0.5 mL intramuscularly once

  • Routine booster vaccination should be 5 or more years after the last recommended dose of the diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) series.
  • May use as a booster dose 8 years after the first tetanus toxoid, reduced diphtheria and acellular pertussis vaccine, adsorbed (Tdap) dose.
  • May use for tetanus prophylaxis in wound management if at least 5 years have elapsed since a previous tetanus toxoid containing vaccine dose.

BOOSTRIX(R): 0.5 mL intramuscularly once
  • Administer 5 years after the last recommended dose of the DTaP series.
  • There are no data to support repeat administration of BOOSTRIX(R), or for its use for primary immunization.
  • May use for tetanus prophylaxis in wound management if no previous dose of any Tdap has been given.


Uses:
  • Booster immunization after completion of primary diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) vaccine series.
  • Tetanus prophylaxis in wound management.

Usual Adult Dose for Tetanus Prophylaxis

ADACEL(R):
10 to 64 years old: 0.5 mL intramuscularly once

  • Routine booster vaccination should be 5 or more years after the last recommended dose of the diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) series.
  • May use as a booster dose 8 years after the first tetanus toxoid, reduced diphtheria and acellular pertussis vaccine, adsorbed (Tdap) dose.
  • May use for tetanus prophylaxis in wound management if at least 5 years have elapsed since a previous tetanus toxoid containing vaccine dose.

BOOSTRIX(R): 0.5 mL intramuscularly once
  • Administer 5 years after the last recommended dose of the DTaP series.
  • There are no data to support repeat administration of BOOSTRIX(R), or for its use for primary immunization.
  • May use for tetanus prophylaxis in wound management if no previous dose of any Tdap has been given.


Uses:
  • Booster immunization after completion of primary diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) vaccine series.
  • Tetanus prophylaxis in wound management.

Usual Pediatric Dose for Diphtheria Prophylaxis

ADACEL(R):
10 to 64 years old: 0.5 mL intramuscularly once

  • Routine booster vaccination should be 5 or more years after the last recommended dose of the diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) series.
  • May use as a booster dose 8 years after the first tetanus toxoid, reduced diphtheria and acellular pertussis vaccine, adsorbed (Tdap) dose.
  • May use for tetanus prophylaxis in wound management if at least 5 years have elapsed since a previous tetanus toxoid containing vaccine dose.

BOOSTRIX(R):
10 years and older: 0.5 mL intramuscularly once
  • Administer 5 years after the last recommended dose of the DTaP series.
  • There are no data to support repeat administration of BOOSTRIX(R), or for its use for primary immunization.
  • May use for tetanus prophylaxis in wound management if no previous dose of any Tdap has been given.


Uses:
  • Booster immunization after completion of primary diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) vaccine series.
  • Tetanus prophylaxis in wound management.

Usual Pediatric Dose for Pertussis Prophylaxis

ADACEL(R):
10 to 64 years old: 0.5 mL intramuscularly once

  • Routine booster vaccination should be 5 or more years after the last recommended dose of the diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) series.
  • May use as a booster dose 8 years after the first tetanus toxoid, reduced diphtheria and acellular pertussis vaccine, adsorbed (Tdap) dose.
  • May use for tetanus prophylaxis in wound management if at least 5 years have elapsed since a previous tetanus toxoid containing vaccine dose.

BOOSTRIX(R):
10 years and older: 0.5 mL intramuscularly once
  • Administer 5 years after the last recommended dose of the DTaP series.
  • There are no data to support repeat administration of BOOSTRIX(R), or for its use for primary immunization.
  • May use for tetanus prophylaxis in wound management if no previous dose of any Tdap has been given.


Uses:
  • Booster immunization after completion of primary diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) vaccine series.
  • Tetanus prophylaxis in wound management.

Usual Pediatric Dose for Tetanus Prophylaxis

ADACEL(R):
10 to 64 years old: 0.5 mL intramuscularly once

  • Routine booster vaccination should be 5 or more years after the last recommended dose of the diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) series.
  • May use as a booster dose 8 years after the first tetanus toxoid, reduced diphtheria and acellular pertussis vaccine, adsorbed (Tdap) dose.
  • May use for tetanus prophylaxis in wound management if at least 5 years have elapsed since a previous tetanus toxoid containing vaccine dose.

BOOSTRIX(R):
10 years and older: 0.5 mL intramuscularly once
  • Administer 5 years after the last recommended dose of the DTaP series.
  • There are no data to support repeat administration of BOOSTRIX(R), or for its use for primary immunization.
  • May use for tetanus prophylaxis in wound management if no previous dose of any Tdap has been given.


Uses:
  • Booster immunization after completion of primary diphtheria, tetanus, and acellular pertussis vaccine adsorbed (DTaP) vaccine series.
  • Tetanus prophylaxis in wound management.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

  • Severe allergic reaction to any of the ingredients
  • Encephalopathy (e.g. coma, decreased consciousness level, prolonged seizures) within 7 day of a previous pertussis containing vaccine

Safety and efficacy have not been established in patients younger than 10 years.

To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS) at: https://vaers.hhs.gov

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • For intramuscular administration only.
  • Do not administer intravenously, intradermally, or subcutaneously.

Storage requirements:
  • Refrigerate; do not freeze.

Reconstitution/preparation techniques:
  • Just before use, shake well to form a uniform, white, cloudy suspension.
  • Do not use if resuspension does not occur with vigorous shaking.
  • Do not use if precipitates or discoloration are present.

IV compatibility:
  • Do not mix with other vaccines or medical products.

Patient advice:
  • Give patients Vaccine Information Statements prior to administration, as required by the National Childhood Vaccine Injury Act of 1986. These materials are available free of charge at www.cdc.gov/vaccines.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by